Post by Médecins Sans Frontières Australia & Médecins Sans Frontières New Zealand

As Gilead Sciences' stockholders convene today for the company’s annual meeting, Médecins Sans Frontières/ Doctors Without Borders (MSF) is calling on them to push the US pharmaceutical giant to sell the highly effective HIV prevention medication lenacapavir to MSF for use in its medical projects across the world. Lenacapavir is a potentially game-changing HIV prevention tool which offers greater choice and longer protection, and high effectiveness for people wishing to protect themselves from acquiring HIV through a twice-yearly injection. Gilead Sciences has refused to sell lenacapavir to MSF directly, despite stating that it has capacity to produce more than the supply it has committed to The Global Fund and continuing to sell to high-income countries, raising questions about Gilead’s ethics and corporate governance. MSF calls on Gilead’s investors to demand that Gilead sell lenacapavir to MSF directly so that MSF can supply this game-changing HIV prevention tool to those who are most in need, and who are not currently covered by the Global Fund agreement.